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Abstract
Background: Gene-based therapy is a new paradigm for the treatment of Parkinson disease (PD) and offers considerable
promise for precise targeting and flexibility to impact multiple pathobiological processes for which small molecule agents
are not available. Some success has been achieved utilizing adeno-associated virus for this approach, but it is likely that the
characteristics of this vector system will ultimately create barriers to progress in clinical therapy. Adenovirus (Ad) vector
overcomes limitations in payload size and targeting. The cellular tropism of Ad serotype 5 (Ad5)–based vectors is regulated
by the Ad attachment protein binding to its primary cellular receptor, the coxsackie and adenovirus receptor (CAR). Many
clinically relevant tissues are refractory to Ad5 infection due to negligible CAR levels but can be targeted by tropism-
modified, CAR-independent forms of Ad. Our objective was to evaluate the role of CAR protein in transduction of dopamine
(DA) neurons in vivo.
Methodology/Principal Findings: Ad5 was delivered to the substantia nigra (SN) in wild type (wt) and CAR transgenic
animals. Cellular tropism was assessed by immunohistochemistry (IHC) in the SN and striatal terminals. CAR expression was
assessed by western blot and IHC. We found in wt animals, Ad5 results in robust transgene expression in astrocytes and
other non-neuronal cells but poor infection of DA neurons. In contrast, in transgenic animals, Ad5 infects SNc neurons
resulting in expression of transduced protein in their striatal terminals. Western blot showed low CAR expression in the
ventral midbrain of wt animals compared to transgenic animals. Interestingly, hCAR protein localizes with markers of post-
synaptic structures, suggesting synapses are the point of entry into dopaminergic neurons in transgenic animals.
Conclusions/Significance: These findings demonstrate that CAR deficiency limits infection of wild type DA neurons by Ad5
and provide a rationale for the development of tropism-modified, CAR-independent Ad-vectors for use in gene therapy of
human PD.
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Introduction
Parkinson disease (PD) is a progressive neurodegenerative
disease which causes a movement disorder characterized by
bradykinesia, resting tremor, rigidity, and postural instability.
These symptoms result primarily from progressive degeneration of
dopamine (DA) producing neurons in the substantia nigra pars
compacta (SNc). Despite progress in treating the symptoms of PD,
no therapy to date has been shown to alter the course of the
neurodegenerative process.
Gene-based therapy is a new paradigm for the treatment of PD
and offers considerable flexibility to impact multiple pathobiolo-
gical processes for which small molecule agents are not available.
Gene-based approaches for PD have been evaluated in Phase I
and II clinical trials [1,2]. These studies have included both
enzyme-based therapies directed towards alleviation of symptoms
[3,4,5,6,7,8,9], and growth factor-based approaches with potential
for neuroprotective and neurorestorative effects [10,11,12,13].
The majority of clinical gene delivery approaches in PD have
employed viral vectors based on adeno-associated virus (AAV).
While some success has been achieved with the AAV approach, it
is likely that the characteristics of this vector system may ultimately
limit its clinical utility. Specifically, AAV vectors offer neither
sufficient flexibility in targeting to enable cell specific delivery, nor
sufficient genomic capacity for larger therapeutic cargoes that may
prove most promising.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12672Use of adenovirus (Ad)-based vectors for gene delivery to the
central nervous system (CNS) may provide a number of
advantages over AAV-based strategies. Ad vectors can deliver up
to 36kb of genetic material, providing space for both therapeutic
transgenes and tissue-specific promoter elements for cell-specific
transcriptional targeting. Further, the ability to modify Ad vector
tropism to target specific tissues (termed transductional targeting)
is well established. The combination of transcriptional and
transductional targeting (double targeting) can provide a high
degree of selectivity and limit off-target effects, leading to
enhanced safety and efficacy [14,15].
Ad serotype 5 (Ad5)-based adenoviral vectors have been
employed for other applications, but are not well suited for PD
gene therapy. When injected into the CNS, previous studies have
established that Ad5-based vectors preferentially infect astrocytes
to a greater extent than neurons [16,17,18]. In this regard, the
tropism of Ad5-based vectors is determined by direct binding of
the Ad5 fiber protein to its primary cellular receptor, the coxsackie
and adenovirus receptor (CAR) [19,20]. The dependence of Ad5
transduction on CAR expression results in a scenario wherein
high-CAR non-target cells can be infected, whereas target tissues,
if low in CAR, remain poorly infected [14,15]. Indeed, many
clinically relevant tissues are often refractory to Ad5 infection due
to negligible CAR levels, but can successfully be targeted by
tropism-modified Ad vectors that utilize alternate receptors
[14,15,21,22,23,24,25].
The expression of CAR in the nervous system and the role of
this protein in targeting Ad5 vectors in the brain have not been
closely examined [26,27]. In this study, we evaluated the ability of
Ad5 vectors to infect dopamine neurons in vivo both in wild type
animals and those genetically engineered to express heterologous
human CAR (hCAR) [27]. We have found that Ad5 delivery to
the wild type C57BL/6 mouse SN results in robust transgene
expression in astrocytes and other non-neuronal cells, but poor
transduction of dopaminergic neurons. In contrast, Ad5 delivery
to transgenic animals expressing hCAR results in increased
transduction of neurons of the SNc. Direct assessment of CAR
protein in the ventral midbrain revealed that there is a relative
paucity of CAR expression in this region in wild type animals,
while nigral CAR expression is markedly increased in hCAR
transgenic animals. These findings demonstrate the importance of
tropism for the efficient transduction of SN neurons by Ad vector,
and provide a rationale for the development of tropism-modified,
CAR-independent Ad vectors for use in gene therapy of human
PD.
Results
Ad5 transduction of dopamine neurons in the SN in wild
type animals in vivo
We assessed the ability of a replication deficient Ad5 vector
encoding green fluorescent protein (GFP) to infect neurons
following stereotaxic injection into the SNc. Immunohistochemical
staining for GFP and tyrosine hydroxylase (TH), a marker of
dopamine neurons, was performed either 7 or 14 days after vector
delivery. In each of eight animals examined, we detected strong
GFP expression in the region of the SNc. In the core of the
injection site, there was extensive labeling of neural and glial
structures with confluent labeling that made distinguishing
individual cellular profiles difficult (Figure 1A). Towards the
periphery of the injection site, the cellular localization of the
staining could be resolved, and the majority of the GFP-positive
cells were small with astrocytic morphology (Figure 2). Few GFP-
positive neurons were detected and only rarely were GFP and TH
double positive neurons observed in wild type animals.
hCAR transgenic animals exhibit enhanced transduction
of dopamine neurons by Ad5 vectors
To better understand the role of CAR in Ad5 transduction of
brain cells, we delivered Ad5 encoding GFP to the SNc of eight
transgenic animals expressing hCAR and eight wild type (wt)
controls. As in the wt animals, in hCAR animals we observed
extensive transduction in the region of the SNc; at the core of the
Figure 1. Ad5 drives high levels of transgene production. Sections through the core of the injection volume in the SN stained for the GFP
transgene, demonstrate the robust levels of expression in this system. This activity made unbiased stereologic counting unfeasible. Panel A is SN of a
wt animal. Panel B is SN of an hCAR transgenic animal.
doi:10.1371/journal.pone.0012672.g001
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many cells with astrocytic morphology (Figure 1B). At the
margins of the injection site, however, we found that in hCAR
animals there was also substantial transduction of TH-positive
neurons within the SNc (Figure 3A–D). Furthermore, we
observed GFP-positive fibers in the ascending medial forebrain
bundle and striatum, a feature rarely observed in the wild type
animals (Figure 3E).
Direct quantitation of the number of neurons in the SNc
infected by Ad5 proved impossible due to the extent of GFP
expression in surrounding non-neuronal cells, particularly in the
core of the injection location where expression was most robust
(Figure 1). To quantify the effect of hCAR expression on the
transduction of the dopamine cells, we instead examined the
anterograde labeling of dopaminergic axons in the dorsolateral
striatum, the primary target of the SNc neurons [28,29,30]. Since
GFP is a soluble protein and diffuses freely within the intracellular
space, these distal axons are filled when the infected neuronal
soma expresses the transgene. We used confocal imaging of
dorsolateral striatal sections stained for GFP and TH, collected
image stacks, and measured the density of GFP-positive fibers
using a threshold approach as described in the Methods. We found
that in the hCAR animals, there was an approximately 100-fold
increase in the number of anterogradely labeled fibers in the
striatum (Percentage of total area occupied, mean 6 SEM of wt
=0.0560.002; hCAR=5.160.3), consistent with increased trans-
duction of TH neurons in the SNc (Figure 4).
CAR Expression in wild type and hCAR transgenic brain
CAR expression has not been closely examined in the brains of
either adult wild type mice or hCAR transgenic animals
[26,27,31]. We therefore performed western blot analysis using
an antibody that recognizes both human and mouse CAR (Santa
Cruz, sc-15405), and observed substantial regional variation in the
abundance of endogenous mCAR protein in adult wild type mice.
There was strong expression of mCAR in the striatum in wild type
mice, while expression in the ventral midbrain (vMB, containing
the SN) was much lower, about one fifth of that in the striatum
(Figure 5A). In the hCAR transgenic mouse, a truncated version
of the hCAR protein is encoded by the transgene, resulting in a
protein with lower molecular mass than that of endogenous
mCAR. This difference in size allowed us to analyze separately the
hCAR and the endogenous mCAR present in the transgenic
animals. We found that in these animals there was abundant
expression of hCAR throughout the brain, with high abundance in
both striatum and vMB (Figure 5A, B), and that the presence of
this transgenic protein did not appreciably alter the expression of
the endogenous mCAR. Thus, in the hCAR transgenic animals
the overall abundance of CAR in the vMB (hCAR together with
mCAR) was five fold higher than in the wild type animals.
Histological analysis of hCAR mice shows transgene
expression localizes to post-synaptic sites in SN and STR
Although mCAR and hCAR were readily detectable via
western blot in the transgenic hCAR animals, histological imaging
of endogenous mCAR proved problematic with the CAR
antibodies and amplification techniques available. We were able
to perform immunohistochemistry for hCAR in the vMB to
identify at a cellular level the localization of hCAR in this region,
allowing us to understand the role this exogenous protein plays in
expanding Ad transduction, and better understand the utility of
tropism-modified ADs. Expression of hCAR was seen throughout
the vMB including within the SNc. Interestingly, most of the
staining was punctate, and did not associate with cellular elements.
Much of the punctate hCAR staining was closely apposed to TH-
positive neurons (Figure 6A–B, D–E), but hCAR was not
detected within the TH-positive neurons themselves (Figure 6C,
F). We studied the cellular localization of the hCAR protein in the
transgenic animals in more detail using dual-label immunohisto-
chemistry. hCAR was not seen to localize with the astrocyte
marker ALDHL1 in the SN (Figure S1 A, B), nor with the
neuronal marker MAP2 in the cortex, SN or STR (Figure S1 C–
H). Both of these experiments suggested that the bulk of the hCAR
protein was located not in cellular perikarya, but rather within the
neuropil. Using an antibody for the protein PSD-95, which is
found at post-synaptic sites and within dendritic spines, we
observed extensive colocalization of PSD-95 with hCAR in both
the SN and STR (Figure 7A–H). In contrast, co-staining with the
pre-synaptic marker synaptophysin revealed that hCAR staining
was often closely opposed to, but not overlapping with,
synaptophysin-positive puncta (Figure S1 I–L).
Discussion
The goal of this study was to assess the utility of adenoviral
vector systems as platforms for CNS gene therapy in Parkinson
disease, and to investigate the factors that modulate the ability of
Ad vectors to deliver therapeutic cargos to dopamine neurons in
the SNc. We have found that native, Ad5 vectors are inefficient in
delivery of genes to SNc dopamine neurons in wild type mice. The
efficiency of delivery is greatly enhanced in animals with
transgenic expression of hCAR, leading to a nearly 100-fold
increase in the density of labeled nigrostriatal axons. Western blot
analysis confirmed that the hCAR animals have a much higher
level of CAR in the region of the SNc. Dual-label studies suggest
Figure 2. Assessment of Ad5 transduction in the SN in vivo.
Confocal immunohistochemical assessment of 1e8 vp of Ad5-GFP
delivered to the mouse SN (red) shows broad transgene expression in
cells of glial morphology (green). The absence of double-labeled cells
indicates Ad5 poorly infects neurons of the SNc (section through
periphery of the injection site). Stereotactic coordinates: AP=3.1,
ML=21.2, DV=24.6. Red = TH–positive neurons, Green = GFP. Bar
=50mm.
doi:10.1371/journal.pone.0012672.g002
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at postsynaptic sites on neurons. Together these data indicate that
tropism and CAR dependence are critically important in
controlling the ability of Ad vectors to deliver genes to dopamine
neurons, and that synaptic sites may be important for entry of the
virus.
The observation that CAR is central to regulating tropism in the
CNS is consistent with prior studies in non-CNS tissues. The
capability of Ad5 to infect specific cell types is correlated to cellular
CAR status, and of direct relevance, CAR-independent Ad vectors
overcome this transductional limitation [22,32,33]. As CAR
functions in cellular adhesion, cancers are frequently deficient in
this protein and therefore refractory to Ad5 transduction.
Development of tropism modified, CAR-independent Ad vectors
has therefore played an important role in allowing the pre-clinical
development of novel tumor-targeted Ad vectors [34,35,36,37].
The first clinical trial evaluating a tropism-modified Ad vector
containing a genetically modified fiber protein, allowing Ad
transduction of cancer cells deficient in CAR (as wt SNc neurons
have herein been shown) has recently been completed and suggests
that this paradigm is safe for use in patients [38], and the
development of other such trials is continuing [39]. The ongoing
development of fiber-modified, CAR-independent forms of Ad5
has greatly expanded the tropism and therefore utility of this
vector system, but these novel Ad vectors have yet to be assessed in
the context of targeting in the CNS for neurodegenerative
diseases, including Parkinson disease.
We used immunohistochemical methods to localize hCAR in
the SN of transgenic animals, and found that the majority of the
hCAR protein localizes to post-synaptic structures in the neuropil
and along the margins of neurons while relatively little is found
within neuronal or glial perikarya. This finding is interesting since
it is known that rabies virus infects neurons through interactions
with the synapse [40]. In wild type mice, however, our western
blot studies suggest that the overall abundance of mCAR in the SN
is quite low, and we were unable to detect the endogenous mCAR
protein by immunohistochemistry in the SN. Together these
observations suggest that the relative paucity of endogenous CAR
Figure 3. hCAR transgenic animals exhibit transduction of dopamine neurons by Ad5 vectors. Delivery of Ad5 to the SN in the hCAR
mouse shows a broadened transduction profile including TH+ neurons by confocal microscopy. Transgene expression extends into the STR terminal
fields. (A) Low power image of the hCAR SN shows a broadened transduction profile of Ad that includes TH-positive neurons, in addition to
astrocytes. Magnification of the region outlined in A shows many TH-positive cells (red, B) staining positive for GFP (green, C) overlaid in D (see
closed arrowheads). GFP-positive cells with astrocyte morphology can also be seen in this region (open arrowheads). (E) Visualization in the STR
shows many fibers labeling with GFP, indicating their transduction by Ad5 delivered in the SNc. Red = TH-positive neurons, Green = GFP, Yellow =
double positive. Scale bar A: 500 mm, B–D: 100 mm, E:5 0mm.
doi:10.1371/journal.pone.0012672.g003
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wild type mice, and that in the hCAR transgenic animal the entry
of the virus is facilitated by synaptically-localized CAR protein. In
the context of the design of gene therapy strategies, induction of
CAR expression is probably not feasible, but development of Ad
viruses with modified tropism is a promising approach, and a
search for Ad viruses which might interact with other proteins
known to be at synaptic sites might prove fruitful.
In these studies, we employed the promiscuous cytomegalovirus
(CMV) promoter in order to visualize gene expression in all cell
types transduced by the Ad5 vector when delivered directly to this
region. Ad vectors do allow for the use of tissue-selective promoters
to target gene expression, and it is likely that use of a neuron-
restricted or DA-specific promoter element (synapsin-1 or DAT)
would have reduced the off-target gene expression in glial and
other non-neuronal cells. On the other hand, transcriptional
restriction would probably not increase the number of TH
neurons labeled in the wild type animals beyond the limited
infectivity we observed. Thus, efficient and selective transduction
of dopamine neurons will likely require both transductional and
transcriptional (double) targeting.
There is an important need for enhanced vector systems in PD
gene therapy. To date, clinical trials in PD have used AAV or
lentiviral vectors. Overall, these approaches have proven relatively
safe and are well tolerated, although evidence for clinical
effectiveness in controlled trials is still lacking [1,4,5,10]. One of
the key issues contributing to the lack of efficacy in the trials
conducted so far is thought to be the relatively low doses of vector
used in many of the initial trials. Studies with higher doses are
planned, but there is concern that this may unmask an increasing
range of adverse effects related to delivery to non-targeted regions.
As an example, recent studies in animal models have suggested
that direct trophic factor delivery to the SN via high doses of AAV
vectors leads to adverse effects on appetite and feeding, perhaps
Figure 4. Quantitation of transgene in the striatal terminal fields. Densitometric analysis of transgene expression in the STR shows the CAR-
dependence for transduction of SNc dopaminergic neurons by Ad delivered to the ventral midbrain. (A) Representative flattened confocal z-stacks
through a 35 mm section of the dorsolateral STR in three wt and hCAR animals. GFP-filled axons projecting from the SNc show the level of neuronal
transduction that is augmented by the addition of hCAR transgene. (B) Densitometric quantification of individual confocal z-planes shows a
significant increase in Ad5 transduction capacity in hCAR mice. (C) Drawing of a sagittal section through the mouse brain shows the location of
vector delivery in the SNc and the location of transgene expression analysis in the STR, approximately 4.25 mm distal from the site of injection. Scale
bar in A=150 mm, Green = GFP. Box plot in B depicts sample minimum, 1
st quartile, median, 3
rd quartile and sample maximum. Statistical
significance assigned using two-tailed Student’s t-test (* indicates P,0.0001). LV = left ventricle, MFB = medial forebrain bundle.
doi:10.1371/journal.pone.0012672.g004
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hypothalamic nuclei [41,42,43] (abstract #186). These findings
reinforce the importance of precise targeting when genetically
delivering highly active therapeutic proteins [44,45,46,47].
Our studies highlight the importance of CAR protein in
regulating the transduction of CNS neurons by Ad5 vectors, and
suggest that modification of vector tropism to target CAR-deficient
cells can achieve more efficient delivery of therapies to these
Figure 5. CAR expression in wild type and hCAR transgenic brain. Regional analysis of CAR protein shows variability in expression levels,
which are elevated in hCAR transgenic animals. (A) A representative immunoblot of CAR protein levels in the ventral midbrain (vMB) and striatum
(STR) shows large differences in expression. The truncated transgenic hCAR protein is seen running with a lower apparent molecular mass. Both
mCAR and hCAR are visualized with the pan-CAR antibody H300. Transgenic hCAR is expressed in both the vMB and STR at a similar level to that of
STR mCAR. (B) Quantitation of total CAR in the ventral midbrain by combining endogenous mCAR and transgenic hCAR shows five-fold more CAR
protein available in this region in hCAR animals. Total CAR protein level of wt animals is considered baseline. Statistical significance assigned using
two-tailed Student’s t-test (* indicates P,0.02).
doi:10.1371/journal.pone.0012672.g005
Figure 6. Histological analysis of hCAR localization shows expression in close apposition to SN neurons. Although we were unable to
visualize mCAR by immunohistochemistry (data not shown), confocal analysis of hCAR in the substantia nigra of transgenic animals (right panels)
showed robust expression throughout the ventral midbrain (D). hCAR was readily seen within the SNc (D, E), and in close apposition to DA-positive
SN neurons (F). (A–C) Left panels show lack of cross-reactivity of antibody RmcB for mCAR. Scale bar A, D: 250 mm, B, E:5 0mm, C, F:1 0mm. Red =
TH-positive neurons, Green = hCAR.
doi:10.1371/journal.pone.0012672.g006
Ad Transduction of DA Neurons
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overexpression of CAR, a strategy that is suitable only for
establishing proof-of-concept in animal models. The most
promising alternative is the use of modified forms of Ad, which
do not depend on CAR for their cellular tropism. As noted above,
modified vectors of this kind have proven therapeutically useful in
treating a variety of non-CNS diseases in many model systems. It
will be important to investigate such tropism-modified Ads to
determine whether they can provide enhanced gene delivery to
SNc dopamine neurons in wild-type animals expressing natively
low levels of CAR, perhaps through other proteins present at post-
synaptic sites. As transductional and transcriptional targeting
modifications are incorporated, Ad promises to develop as a
flexible platform for the delivery of novel therapeutics, allowing
targeted and controlled delivery, while minimizing side effects.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Institutional
Animal Care and Use Committee of the University of Alabama at
Birmingham (UAB Animal Welfare Assurance Number: A3255-
01; Study approval number: 100208706) and conducted in
accordance with their and National Institutes of Health guidelines.
Subjects and Surgical Procedure
Mice were housed under 12 hour light/12 hour dark cycle and
were provided standard mouse diet. Sixteen wild type C57B/6
mice and eight hCAR transgenic C57B/6 mice (a generous gift
from Dr. S Pettersson, Karolinska Institute, Stockholm, Sweden)
received vector delivered to the unilateral SN. For experiments
outlined in Figure 3, these animals were aged between 16–24
weeks. Transgenic mice express the human CAR gene lacking the
cytoplasmic tail, under control of the human ubiquitin-C
promoter, allowing hCAR to be expressed in a variety of tissues
including the liver, kidney, heart, lungs, brain, and muscle [27].
Under isoflurane anesthesia, the mice were injected stereotaxically
with Ad5 into the right SN; coordinates were anterior-posterior,
23.2 mm from bregma, medio-lateral, 21.2 from midline and
dorso-ventral, 24.6 from the dura. Mice received 2.5610
8 vp/
animal in a volume of 2 ml at a flow rate of 0.25 ml/minute over
eight minutes, followed by two minutes for diffusion before the
syringe was slowly removed.
Adenovirus vector
The Ad5 vector used in this study was replication deficient (E1
deleted), containing two bicistronic reporter gene cassettes driving
GFP and firefly luciferase off separate cytomegalovirus promoters,
as previously described (A kind gift from Dr. Wu, University of
Alabama at Birmingham) [22].
Immunohistochemistry
Two weeks post-injection, animals were deeply anesthetized and
transcardially perfused with 4% paraformaldehyde in phosphate
buffered saline (PBS). Brains were removed and post-fixed in the
same fixative for two hours at room temperature before
cryopreservation by impregnation with 30% sucrose in PBS,
approximately two days at 4uC. Tissue was flash frozen in
isopentane on dry ice and 40 mm sections were cut using a sliding
microtome and collected as free-floating tissue in PBS:Glycerol,
1:1. For GFP and TH staining, floating sections were blocked with
10% normal goat serum for 60 minutes followed by incubation
with mouse anti-GFP 1:20,000 (MAB3580, Millipore, Billerica,
MA) and rabbit anti-TH 1:2000 (P40101-0, PelFreez Biologicals,
Rogers, AR) for 48 hours at 4uC. Tissue was then washed in PBS,
followed by incubation in a 1:500 dilution of alexa-488 conjugated
Figure 7. Transgenic hCAR localizes to post-synaptic structures. Assessing the expression pattern of exogenous hCAR in the SN and STR of
transgenic animals, we found co-localization with the post-synaptic density marker PSD95 (A–H, closed arrowheads indicate areas of co-localization).
SN= substantia nigra, STR = striatum. Bars in A and E=50mm, bars in B and F=5mm.
doi:10.1371/journal.pone.0012672.g007
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conjugated goat anti-rabbit (Jackson Immunoresearch, West
Grove, PA) secondary antibodies. Slides were then coverslipped
with Vectashield mounting medium (Vector Labs, Burlingame,
CA). For DAB chromogenic staining technique, tissue was
incubated in 3% H202 in methanol for 10 minutes before
application of primary antibody. Biotinylated secondary goat
anti-mouse was used at 1:2000 dilution, followed by amplification
with the ABC system (PK-7100, Vector Labs) and chromogenic
precipitation with DAB (SK-4100, Vector Labs).
To visualize hCAR protein, we utilized tyramide signal
amplification (TSA, Perkin Elmer, Waltham, MA), on the anti-
CAR monoclonal antibody RmcB (05-644, Millipore, Billerica,
MA) following manufacturer’s recommended instructions. Briefly,
peroxidase is quenched with 3% H2O2 in methanol, tissue is
washed, and blocked with supplied buffer, 30 minutes. TH,
ALDHL1 (1:250, Abcam, Cambridge, MA), MAP2 (1:500,
Abcam), Synapsin (1:500, Dako, Carpinteria, CA), PSD95
(1:100, Santa Cruz Biotechnology, Santa Cruz, CA), and RmcB
(1:600 dilution) primary antibodies are incubated overnight at
4uC. Tissue is then washed and secondary antibody is applied (for
RmcB, HRP-conjugated goat anti-mouse, 1:500) for 60 minutes at
room temperature. Tissue is washed, and fluorescein amplification
reagent is incubated 8 minutes. Tissue is washed and coverslipped
with Vectashield aqueous mounting medium.
Imaging
Confocal images were captured using a Leica TCS-SP5 laser
scanning confocal microscope. The images were processed using
the Leica software and exported as Tiff files and processed using
Adobe Photoshop CS3. For quantitation of percent area occupied,
the threshold approach was utilized. All tissue analyzed was
stained simultaneously and Z-stacks (2 mm step size) of GFP-
stained sections through the dorsolateral STR were obtained with
identical confocal settings. These files were then loaded into the
ImageJ software package, where stacks were converted into 8-bit
grayscale images. A threshold level of 83–255 was set for all
images, and percent area was measured. Statistics were calculated
using two tailed Student’s t-test.
Immunoblotting
Tissue was rapidly extracted from freshly sacrificed animals,
dissected to subregions, immediately flash frozen at 280uCi n
isopentane on dry ice and stored at 280uC. To prepare for
immunoblotting, cells were dissociated in homogenization buffer
(320 mM sucrose, 10 mM Tris-HCL, 5 mM EDTA, complete
protease inhibitor cocktail/PhosSTOP phosphatase inhibitor
cocktail, Roche Applied Science) using a tissue homogenizer
briefly at medium setting. A cell-intact pellet was obtained by
centrifugation at 15000 rpm at 4uC for 16 minutes. Pellet was
resuspended in TE buffer (10 mM Tris-HCL, 5 mM EDTA,
pH 7.4) and sonicated on ice for 10 seconds. Protein concentra-
tions were then determined by the bicinchoninic acid assay (BCA)
and samples were diluted to a final concentration of 1 mg/ml in
TE buffer. Boiled samples were mixed with 26reducing stop
buffer (0.25 M Tris–HCl, pH 6.8, 5 mM EDTA, 5 mM EGTA,
25 mM dithiothreitol, 2% SDS, 10% glycerol, and bromophenol
blue as the tracking dye), boiled for 10 minutes, and run on 8%
SDS-polyacrylamide gels before transfer to PVDF membrane.
Blots were blocked in 5% nonfat dry milk in TBST (20 mM Tris–
HCl, pH 7.6, 137 mM NaCl, 0.05% Tween 20) for 1 hour at
room temperature, then incubated with anti-CAR antibody
(H300, Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
overnight at 4uC. Membranes were then washed three times with
TBST and incubated with HRP-conjugated secondary antibody
for 1 hour at room temperature. The membranes were rinsed 6
times for 10 min with TBST, and developed with the enhanced
chemiluminescence method. Optical density was quantitated with
ImageJ software package and statistics was calculated using two
tailed Student’s t-test.
Supporting Information
Figure S1 hCAR transgene expression does not localize with
astrocytes, neurons, or the pre-synaptic structures. hCAR does not
co-localize with the astrocyte marker ALDHL1 in the SN (A, B),
nor does it localize to neuronal dendrites or cell bodies (MAP2
staining, C–H). Staining for the pre-synaptic marker synaptophy-
sin showed close association of staining with hCAR (I–L, closed
arrowheads indicate adjacent areas). SN = substantia nigra, CTX
= cortex, STR = striatum. Bars in A and E =100 mm; bars in C
and G =50 mm; bars in B, D, F, H =20 mm; bar in I =10 mm;
bar in J for J–L =2 mm.
Found at: doi:10.1371/journal.pone.0012672.s001 (8.32 MB TIF)
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